Coagulase-negative staphylococcal prosthetic valve endocarditis--a contemporary update based on the International Collaboration on Endocarditis: prospective cohort study.
OBJECTIVE
To describe the contemporary features of coagulase-negative staphylococcal (CoNS) prosthetic valve endocarditis (PVE).


METHODS
Observational study of prospectively collected data from a multinational cohort of patients with infective endocarditis. Patients with CoNS PVE were compared to patients with Staphylococcus aureus and viridans streptococcal (VGS) PVE.


METHODS
The International Collaboration on Endocarditis-Prospective Cohort Study (ICE-PCS) is a contemporary cohort of patients with infective endocarditis from 61 centres in 28 countries.


METHODS
Adult patients in the ICE-PCS with definite PVE and no history of injecting drug use from June 2000 to August 2005 were included.


METHODS
None.


METHODS
Heart failure, intracardiac abscess, death.


RESULTS
CoNS caused 16% (n = 86) of 537 cases of definite non-injecting drug use-associated PVE. Nearly one-half (n = 33/69, 48%) of patients with CoNS PVE presented between 60 days and 365 days of valve implantation. The rate of intracardiac abscess was significantly higher in patients with CoNS PVE (38%) than in patients with either S aureus (23%, p = 0.03) or VGS (20%, p = 0.05) PVE. The rate of abscess was particularly high in early (50%) and intermediate (52%) CoNS PVE. In-hospital mortality was 24% for CoNS PVE, 36% for S aureus PVE (p = 0.09) and 9.1% for VGS PVE (p = 0.08). Meticillin resistance was present in 68% of CoNS strains.


CONCLUSIONS
Nearly one-half of CoNS PVE cases occur between 60 days and 365 days of prosthetic valve implantation. CoNS PVE is associated with a high rate of meticillin resistance and significant valvular complications.
Chu
V H
VH
Duke University Medical Center, Durham, NC 27710, USA. chu00009@mc.duke.edu
Miro
J M
JM
Hoen
B
B
Cabell
C H
CH
Pappas
P A
PA
Jones
P
P
Stryjewski
M E
ME
Anguera
I
I
Braun
S
S
Muñoz
P
P
Commerford
P
P
Tornos
P
P
Francis
J
J
Oyonarte
M
M
Selton-Suty
C
C
Morris
A J
AJ
Habib
G
G
Almirante
B
B
Sexton
D J
DJ
Corey
G R
GR
Fowler
V G
VG
D000368:Aged; D001705:Bioprosthesis; D003030:Coagulase; D003428:Cross Infection / Q000188:drug therapy / Q000382:microbiology / Q000401:mortality; D004352:Drug Resistance, Microbial; D004697:Endocarditis, Bacterial / Q000188:drug therapy / Q000382:microbiology* / Q000401:mortality; D005260:Female; D006350:Heart Valve Prosthesis; D017052:Hospital Mortality; D006801:Humans; D008297:Male; D008875:Middle Aged; D011183:Postoperative Complications / Q000188:drug therapy / Q000382:microbiology* / Q000401:mortality; D011446:Prospective Studies; D016459:Prosthesis-Related Infections / Q000188:drug therapy / Q000382:microbiology* / Q000401:mortality; D013203:Staphylococcal Infections / Q000188:drug therapy / Q000401:mortality; D013211:Staphylococcus aureus; D018709:Statistics, Nonparametric; D013997:Time Factors
D003030:Coagulase